The Pharmaceutical industry has historically played a role in contracting with the Federal Government for the development of products to protect the general overall health and well-being of the nation. Since the events of 9/11, the Federal Government is increasingly seeking new products from the Pharmaceutical industry to address potential bio-terrorism threats. In addition, new health risks periodically emerge such as Avian Flu, Ebola and Zika Virus, for which there is an immediate need for development of a product to combat these risks.
The Department of Health and Human Services (HHS) and more specifically the National Institute of Health (NIH) has been a partner in supporting this industry in their R&D efforts. Increasingly, more contracting opportunities have resulted from HHS’ Biomedical Advanced Research and Development Authority (BARDA) and the DoD’s Defense Advanced Research Projects Agency (DARPA) to combat the threat of bioterrorism. We have supported a number of Pharmaceutical companies in various aspects of the federal contract process ranging from traditional contracts to Other Transaction Authority (OTA) contracts.
Relevant Contracts/Contracting Agencies:
National Institute of Health (NIH) Grants & Contracts
Defense Logistics Agency Contracts
United States Army Medical Research Acquisition Activity (USAMRAA)
Biomedical Advanced Research and Development Authority (BARDA)
Defense Advanced Research Projects Agency (DARPA)
Cost Accounting Structure Design & Redesign
Bid & Proposal Preparation
Contract Accounting & Billing Process Development
Incurred Cost Submissions